Tianyang Liu

Tianyang Liu

China National Health Development Research Center, China

Title: Estimating the value of pneumococcal conjugate vaccination in India: State-level and national-level analyses


Tianyang Liu did her MHS in health economics in May 2013 from Johns Hopkins Bloomberg School of Public Health. Right after graduation, she worked as a health economist in the International Vaccine Access Center, responsible for the project analyzing economic impact of 3 childhood vaccines in India. Currently, she is working as a researcher in the China National Health Development Research Centre, which is attached to the Ministry of Health. As part of her research interest, she is now focusing on a project analyzing the influenza vaccine uptake among health care workers in hospitals in China


Background and aims: Streptococcus pneumoniae is a leading cause of childhood pneumonia and meningitis morbidity/mortality in India. Our objective was to project the health/economic benefits of achieving high coverage of pneumococcal conjugate vaccine (PCV) in India. Methods: We adapted an existing model and synthesized locally available data to estimate the potential impact of PCV in India and selected states (Bihar, Delhi, Maharashtra, Tamil Nadu) in terms of averting: Deaths/cases, disease costs and productivity loss for a single year with three theoretical coverage scenarios for PCV (72%, 80%, 90%). Sensitivity analyses were performed to evaluate the impact of model assumptions. Results: PCV in India could result in $427million (range $188.1-$719.3million) of cost savings to the public sector in a single year. Up to $2.4million of these savings is attributable to averted treatment costs and $67.4million to meningitis-related productivity loss averted. Caretaker productivity and transportation costs averted accounted for $1.2million in savings. Averted lost productivity due to premature death represented 83% of these savings at $355.9million. The greatest savings to the public sector ($57.4million) occurred in Bihar where the burden of disease is high, followed by Maharashtra with $7million and Delhi with $2.5million. For the private sector in India, the benefits of achieving 90% of PCV in a single year result in $1.7 billion savings. For Bihar, Maharashtra and Delhi, savings to the private sector translated into $225million, $27.5million and $10.7million, respectively. Conclusion: Achieving high coverage of PCV results in substantial cost savings to the public and private sectors in India.